Prime Capital Investment Advisors LLC Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Prime Capital Investment Advisors LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 4.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 170,314 shares of the biopharmaceutical company’s stock after selling 8,731 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Pfizer were worth $4,929,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Savvy Advisors Inc. grew its stake in Pfizer by 14.4% during the 3rd quarter. Savvy Advisors Inc. now owns 24,339 shares of the biopharmaceutical company’s stock worth $704,000 after buying an additional 3,058 shares during the last quarter. Platform Technology Partners grew its stake in Pfizer by 16.9% in the third quarter. Platform Technology Partners now owns 22,590 shares of the biopharmaceutical company’s stock valued at $654,000 after purchasing an additional 3,268 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Pfizer by 4.3% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 13,118,764 shares of the biopharmaceutical company’s stock valued at $379,657,000 after purchasing an additional 544,418 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its holdings in Pfizer by 52.6% during the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 31,723 shares of the biopharmaceutical company’s stock valued at $919,000 after purchasing an additional 10,938 shares during the last quarter. Finally, WealthPlan Investment Management LLC lifted its holdings in shares of Pfizer by 4.5% during the third quarter. WealthPlan Investment Management LLC now owns 75,136 shares of the biopharmaceutical company’s stock worth $2,174,000 after buying an additional 3,216 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays increased their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.58.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Stock Performance

NYSE:PFE opened at $26.18 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a 50 day simple moving average of $28.84 and a two-hundred day simple moving average of $28.67. The company has a market capitalization of $148.36 billion, a PE ratio of 35.38, a P/E/G ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period last year, the business posted ($0.17) EPS. Research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.42%. Pfizer’s payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.